Alloy's menopause pages make it possible to see several prescription forms before starting an assessment. That can make a first conversation less unfamiliar. It can also make the product feel settled before a clinician has considered the symptoms and history that should guide the choice.
We read Alloy's HRT, patch and progesterone descriptions on October 13, 2026. This is a public-source review of the offering, without a patient consultation, purchase or test of clinical results. The useful next step is an understandable care proposal, rather than selecting a medicine from a display.
Keep the exact prescription, supply period and consultation fee together when comparing Alloy's offer.
Begin with the concern you want help with
Alloy describes a menopause assessment and physician communication before prescribing. Start that exchange with what has changed, what is troublesome and what you have already tried. A prescription is one possible result of evaluation, not something guaranteed by completing an intake or paying an assessment fee.
Our introduction to menopause HRT can help organize the conversation. Ask what can be assessed remotely and when an examination or another clinician would be needed. The website's service description does not tell us which route will be appropriate for a particular reader.
Reading behind this section: Alloy: HRT options (checked October 13, 2026) · Alloy: estradiol patch offer (checked October 13, 2026) · Alloy: progesterone product and supply (checked October 13, 2026) · ACOG: hormone therapy for menopause · FDA: understanding compounded-drug risks
Notice the different treatment forms
The public menu includes estradiol pills, patches, gel and spray, with progesterone listed separately. Vaginal estrogen also appears in the broader catalog. These entries should not be treated as interchangeable ways to address every symptom. A local vaginal treatment and systemic hormone therapy can serve different purposes.
Read systemic versus vaginal estrogen with the proposed prescription in mind. Ask for the name of the finished medicine and its intended role. Alloy describes FDA-approved hormone options, but that does not establish approval of every product sold elsewhere in its catalog or identify the manufacturer of your dispensed order.
Reading behind this section: Alloy: HRT options (checked October 13, 2026) · Alloy: estradiol patch offer (checked October 13, 2026) · Alloy: progesterone product and supply (checked October 13, 2026) · ACOG: hormone therapy for menopause · FDA: understanding compounded-drug risks
Translate a monthly display into the actual purchase
The current HRT page lists estradiol pills from $39.99 a month, gel or spray from $69.99 and patches at $100. The dedicated patch page agrees with the $100 display and describes supply and billing every three months. It also lists a separate $49 one-time consultation.
At the displayed patch rate, three months represents $300 for that medication component. This arithmetic is not a personal checkout quote: another prescribed medicine or applicable transaction terms may change the amount. Use our cost guide to record the charge due now and the future payment separately, instead of budgeting only the smallest monthly figure.
Reading behind this section: Alloy: HRT options (checked October 13, 2026) · Alloy: estradiol patch offer (checked October 13, 2026) · Alloy: progesterone product and supply (checked October 13, 2026) · ACOG: hormone therapy for menopause · FDA: understanding compounded-drug risks
Ask about the second medicine when it is relevant
Alloy's progesterone page displays a starting price of $23 for one month while describing a three-month supply. Confirm the selected quantity, price and actual product. The page calls it an FDA-approved bioidentical daily pill but does not provide every manufacturer, strength or excipient detail needed to identify a dispensed capsule.
For a person with a uterus considering systemic estrogen, appropriate progestogen protection is a clinical question to discuss. It should not be inferred from whether two product cards sit together. Our risks-and-benefits guide encourages that conversation without selecting a regimen or assuming that every person needs the same combination.
Reading behind this section: Alloy: HRT options (checked October 13, 2026) · Alloy: estradiol patch offer (checked October 13, 2026) · Alloy: progesterone product and supply (checked October 13, 2026) · ACOG: hormone therapy for menopause · FDA: understanding compounded-drug risks
Keep access and response time distinct
Alloy advertises ongoing doctor messaging with its service. That describes a communication route; it is not our measurement of how quickly a side-effect question is answered. Ask who handles clinical messages, how a medication adjustment is reviewed and which concerns require urgent local care instead.
Also ask what happens when a prescription changes before a three-month supply is used. Determine how renewals are paused, whether a new order creates another charge and how records can be shared with your usual clinician. We did not enter the patient portal or test delivery, and a shipping promise cannot establish the quality of medical follow-up.
Reading behind this section: Alloy: HRT options (checked October 13, 2026) · Alloy: estradiol patch offer (checked October 13, 2026) · Alloy: progesterone product and supply (checked October 13, 2026) · ACOG: hormone therapy for menopause · FDA: understanding compounded-drug risks
Compare the arrangement that you would actually use
Midi's review describes an appointment-centered comparison, while AquaVitality covers regional clinic plans. Compare the same expected period, prescribed medicines and level of contact. None of these public descriptions establishes better symptom relief or clinician performance than the others.
Alloy's visible product menu can make preliminary research easier. A useful final proposal still needs the clinician's reasoning, the complete bill and a follow-up plan you understand. If a term remains unclear, keep it as a question for the care team rather than filling the gap with an assumption about what a menopause service usually includes.
Reading behind this section: Alloy: HRT options (checked October 13, 2026) · Alloy: estradiol patch offer (checked October 13, 2026) · Alloy: progesterone product and supply (checked October 13, 2026) · ACOG: hormone therapy for menopause · FDA: understanding compounded-drug risks
Our source notes
- Alloy: HRT options (checked October 13, 2026)
Official source checked October 13, 2026. Provider descriptions establish advertised terms, not independently verified treatment outcomes.
- Alloy: estradiol patch offer (checked October 13, 2026)
Official source checked October 13, 2026. Provider descriptions establish advertised terms, not independently verified treatment outcomes.
- Alloy: progesterone product and supply (checked October 13, 2026)
Official source checked October 13, 2026. Provider descriptions establish advertised terms, not independently verified treatment outcomes.
- ACOG: hormone therapy for menopause
Official source checked October 13, 2026. Provider descriptions establish advertised terms, not independently verified treatment outcomes.
- FDA: understanding compounded-drug risks
Official source checked October 13, 2026. Provider descriptions establish advertised terms, not independently verified treatment outcomes.
